Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce Cree(University of California, San Francisco), Jeffrey L. Bennett(University of Colorado Anschutz Medical Campus), Ho Jin Kim(National Cancer Center), Brian G. Weinshenker(Mayo Clinic in Arizona), Sean J Pittock(Mayo Clinic in Arizona), Dean M. Wingerchuk(Mayo Clinic in Arizona), Kazuo Fujihara(Southern Tohoku General Hospital), Friedemann Paul(Max Delbrück Center), Gary Cutter(University of Alabama at Birmingham), Romain Marignier(Observatoire Français de la Sclérose en Plaques), Ari Green(University of California, San Francisco), Orhan Aktaş(Heinrich Heine University Düsseldorf), Hans‐Peter Hartung(Heinrich Heine University Düsseldorf), Fred Lublin(Icahn School of Medicine at Mount Sinai), Jörn Drappa, Gerard Barron, Soraya Madani, John N. Ratchford, Dewei She, Daniel Cimbora, Eliezer Katz
Cited by 712
Abstract
Related Papers
No related papers found
Powered by citation graph analysis